Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) - Stock analysts at Leerink Partnrs lifted their Q4 2024 EPS estimates for Amicus Therapeutics in a research note issued to investors on Monday, January 20th. Leerink Partnrs analyst J. Schwartz now forecasts that the biopharmaceutical company will earn ($0.03) per share for the quarter, up from their previous forecast of ($0.04). The consensus estimate for Amicus Therapeutics' current full-year earnings is ($0.04) per share. Leerink Partnrs also issued estimates for Amicus Therapeutics' Q1 2025 earnings at ($0.05) EPS.
Other analysts have also issued reports about the company. Cantor Fitzgerald reissued an "overweight" rating and issued a $21.00 price objective on shares of Amicus Therapeutics in a report on Wednesday, January 15th. StockNews.com lowered Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Wednesday, December 18th. Needham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a research note on Monday, January 13th. JPMorgan Chase & Co. boosted their target price on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the company an "overweight" rating in a research note on Tuesday, November 12th. Finally, Bank of America raised their price target on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a "buy" rating in a research report on Thursday, October 17th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $16.88.
Read Our Latest Analysis on FOLD
Amicus Therapeutics Stock Up 0.3 %
Shares of Amicus Therapeutics stock traded up $0.03 during trading on Wednesday, reaching $9.54. The company had a trading volume of 1,635,456 shares, compared to its average volume of 2,373,443. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15. Amicus Therapeutics has a fifty-two week low of $8.78 and a fifty-two week high of $14.03. The firm's fifty day moving average is $9.64 and its 200-day moving average is $10.52. The company has a market cap of $2.85 billion, a price-to-earnings ratio of -28.06, a price-to-earnings-growth ratio of 1.51 and a beta of 0.62.
Institutional Investors Weigh In On Amicus Therapeutics
Institutional investors have recently bought and sold shares of the stock. Wellington Management Group LLP raised its stake in shares of Amicus Therapeutics by 13.5% in the 3rd quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company's stock worth $255,936,000 after buying an additional 2,856,101 shares in the last quarter. Millennium Management LLC grew its holdings in Amicus Therapeutics by 1,758.9% during the second quarter. Millennium Management LLC now owns 1,894,176 shares of the biopharmaceutical company's stock worth $18,790,000 after acquiring an additional 1,792,277 shares during the period. Point72 Asset Management L.P. bought a new stake in Amicus Therapeutics in the third quarter worth about $13,530,000. Assenagon Asset Management S.A. lifted its holdings in Amicus Therapeutics by 141.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 2,037,896 shares of the biopharmaceutical company's stock valued at $21,765,000 after acquiring an additional 1,192,489 shares during the last quarter. Finally, Squarepoint Ops LLC boosted its position in shares of Amicus Therapeutics by 159.1% during the 2nd quarter. Squarepoint Ops LLC now owns 650,555 shares of the biopharmaceutical company's stock valued at $6,454,000 after purchasing an additional 399,449 shares in the last quarter.
Insider Buying and Selling at Amicus Therapeutics
In other news, CEO Bradley L. Campbell sold 7,901 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $12.50, for a total value of $98,762.50. Following the completion of the transaction, the chief executive officer now owns 886,654 shares of the company's stock, valued at approximately $11,083,175. This represents a 0.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders sold 22,901 shares of company stock valued at $259,863 in the last ninety days. Company insiders own 2.20% of the company's stock.
About Amicus Therapeutics
(
Get Free Report)
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
Featured Stories
Before you consider Amicus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amicus Therapeutics wasn't on the list.
While Amicus Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
